Vertex Pharmaceuticals EVP sells $1.62 million in stock

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory & Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), has sold 3,242 shares of the company’s common stock. The transaction, executed on March 10, 2025, was conducted under a pre-established trading plan and amounted to approximately $1.62 million, with each share priced at $499.99. Following the sale, Tatsis retains ownership of 51,239 shares in the company. This transaction was made as part of a Rule 10b5-1 trading plan, which was set up in November 2024. According to InvestingPro data, the stock is trading near its 52-week high of $519.88, and management has been actively buying back shares. For deeper insights into insider trading patterns and 13 additional exclusive ProTips, consider exploring InvestingPro’s comprehensive analysis tools and Pro Research Report.

In other recent news, Vertex Pharmaceuticals Inc.’s non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE:UNH).’s coverage. However, the drug is placed in a higher cost tier, specifically tier 3, which is typically reserved for "non-preferred" brand drugs. This classification means that while Journavx will be covered, it will likely cost patients more than drugs categorized in tiers 1 or 2. Meanwhile, Vertex, Inc. reported its fourth-quarter results, posting adjusted earnings per share of $0.15, slightly above analyst estimates of $0.14. The company’s revenue for the quarter reached $178.5 million, surpassing the consensus of $176.9 million and marking a 15.2% year-over-year increase. Despite this, Vertex’s guidance for the first quarter of 2025 fell short, with projected revenue of $175-178 million, below the analyst projections of $180.3 million. For the full year 2025, the company expects revenue to align with the $764 million consensus estimate. The company highlighted additional R&D investments of $14-16 million for AI initiatives and emerging technologies, which they believe will contribute to long-term growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.